Literature DB >> 2296993

Azidothymidine (zidovudine) transport by the human placenta.

S Schenker1, R F Johnson, T S King, R S Schenken, G I Henderson.   

Abstract

The diagnosis of Acquired Immunodeficiency Syndrome (AIDS) is increasingly made in pregnant women, and the disease may be transmitted to the fetus. Azidothymidine (AZT, Zidovudine) is the one therapeutic agent of some promise in this condition. As there is no information on the transport of this drug by the human placenta, such studies were carried out using the single cotyledon placental perfusion system and human placental vesicles. AZT crossed the placenta readily and bidirectionally. The transfer rate was about 70% that of a freely diffusible reference marker, antipyrine, and was comparable in both directions. There was no evidence of active or carrier-mediated transport and no glucuronidated metabolites of the drug were identified in either maternal or fetal compartments. The authors believe that the drug crosses the placenta by diffusion, consistent with its lipophilicity and transport into various blood cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296993     DOI: 10.1097/00000441-199001000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  17 in total

1.  Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT.

Authors:  Y Sai; T Nishimura; S Shimpo; T Chishu; K Sato; N Kose; T Terasaki; C Mukai; S Kitagaki; N Miyakoshi; Y-S Kang; E Nakashima
Journal:  Pharm Res       Date:  2008-03-12       Impact factor: 4.200

2.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.

Authors:  Zufei Zhang; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-01-03       Impact factor: 3.922

Review 3.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

4.  Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Authors:  C Vinot; L Gavard; J M Tréluyer; S Manceau; E Courbon; J M Scherrmann; X Declèves; D Duro; G Peytavin; L Mandelbrot; C Giraud
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 5.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys.

Authors:  E M Cretton; R F Schinazi; H M McClure; D C Anderson; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

8.  Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina).

Authors:  C M Pereira; C Nosbisch; W L Baughman; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Transfer of dideoxyinosine across the human isolated placenta.

Authors:  G I Henderson; A B Perez; Y Yang; R L Hamby; R S Schenken; S Schenker
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

Review 10.  Guidelines for the use of zidovudine in pregnant women with HIV infection.

Authors:  M De Santis; G Noia; A Caruso; S Mancuso
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.